Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma
Authors:
- Sixuan PanSPSixuan Pan
- Kanish MirchiaKMKanish Mirchia
- Emily PayneEPEmily Payne
- S. John LiuSLS. John Liu
- Nadeem Al-AdliNANadeem Al-Adli
- Zain PeeranZPZain Peeran
- Poojan ShuklaPSPoojan Shukla
- Jacob S. YoungJYJacob S. Young
- Rohit GuptaRGRohit Gupta
- Jasper WuJWJasper Wu
- Joanna PakJPJoanna Pak
- Tomoko OzawaTOTomoko Ozawa
Open Access
- 23 September 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Abstract
Tumor suppressor NF1 is recurrently mutated in glioblastoma, leading to aberrant activation of Ras/rapidly accelerated fibrosarcoma (RAF)/MEK signaling. However, how tumor heterogeneity shapes the molecular landscape and efficacy of targeted therapies remains unclear. Here, we combined bulk and single-cell genomics of human somatic NF1 -mutant, isocitrate dehydrogenase (IDH) wild-type glioblastomas with functional studies in cell lines and mouse intracranial tumor models to identify mechanisms of tumor heterogeneity underlying clinical outcome and MEK inhibitor response. Targeted DNA sequencing identified CDKN2A/B homozygous deletion as a poor prognostic marker in somatic NF1 -mutant, but not NF1 wild-type, glioblastoma. Single-nucleus RNA sequencing of human patient NF1 -mutant glioblastomas demonstrated that mesenchymal-like (MES-like) tumor cells were enriched for MEK activation signatures. Single-cell RNA-sequencing of mouse intracranial glioblastomas treated with the MEK inhibitor selumetinib identified distinct responses among tumor subpopulations. MEK inhibition selectively depleted MES-like cells, and selumetinib-resistant MES-like cells upregulated Ras signaling while resistant non-MES cells expressed markers of glial differentiation. Finally, genome-wide CRISPR interference screens validated Ras/RAF/MEK signaling as a key mediator of selumetinib response. Repression of the RAF regulator SHOC2 sensitized glioblastomas to selumetinib in vitro and in vivo, suggesting a synergistic treatment strategy. Taken together, these results highlighted the heterogeneity of NF1 -mutant glioblastomas and informed future combination therapies.Keywords
Funding Information
- NTAP (Francis Collins Scholar Award)
This publication has 52 references indexed in Scilit:
- Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Acta Neuropathologica, 2022
- Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastomaCancer Cell, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- An Integrative Model of Cellular States, Plasticity, and Genetics for GlioblastomaCell, 2019
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the MicroenvironmentCancer Cell, 2017
- RAS Proteins and Their Regulators in Human DiseaseCell, 2017
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study groupCancer, 1981